) to jointly develop and market cancer treatments, as it looks to expand its cancer franchise.
Genmab could receive up to $3.15 billion in additional development, regulatory and sales milestone payments.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: